SEC Form SC 13G filed by NeuroBo Pharmaceuticals Inc.

3/28/23 3:30:53 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NRBO alert in real time by email

SC 13G 1 NeuroBo.doc.txt STRATEGIC RISK LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Neurbo Pharmaceuticals, Inc. U n d e r t h e S e c u r i t i e s E x c h a n g e A c t o f 1 9 3 4 ( A m e n d m e n t N o . ) * ( N a m e o f I s s u e r ) Common Stock, Par Value .001 per share 64132R206 ( T i t l e o f C l a s s o f S e c u r i t i e s ) ( C U S I P N u m b e r ) Strategic Risk, LLC. 228 Park Ave S. PMB 828333 NY, NY 10003 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) March 20, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? Rule 13d-1(b) ?X Rule 13d-1(c) ? Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 64132 R206 13G Page 2 of 3 Pages 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Strategic Risk, LLC. EIN: 92-2981683 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION United States, New York NUMBER OF SHARES BENEFICIA LLY 5. SOLE VOTIN G POWER 1, 202, 833 OWNED BY EACH REPORTIN G PERSON WITH 6. SHARE D VOTIN G POWER 00,00 0 7. SOLE DISPO SITIV E POWER 1 , 2 0 2 , 8 3 3 8. SHARE D DISPO SITIV E POWER 00,000 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1, 202, 833 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.3% 12. TYPE OF REPORTING PERSON (see instructions) PN CUSIP No. 64132R 206 13G Page 3 of 3 Pages Item 1. (a) Name of Issuer Neurbo Pharmaceutica ls, Inc. (the Issuer) (b) Address of Issuer?s Principal Executive Offices Item 2. 200 Barkley Street, office 19th Fl. Boston, MA 02116 (a) Name of Person Filing Strategic Risk, LLC. (b) Address of the Principal Office or, if none, residence 228 Park Ave S. PMB 828333 NY, NY 10003 (c) Citiz enshi p United States (d) Title of Class of Securities Common Stock, Par Value .001 per share (e) CUSIP Number 64132R206 Item 3. If this statement is filed pursuant to ??240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) ? Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) ? Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) ? Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) ? Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) ? An investment adviser in accordance with ?240.13d- 1(b)(1)(ii)(E); (f) ? An employee benefit plan or endowment fund in accordance with ?240.13d-1(b)(1)(ii)(F); (g) ? A parent holding company or control person in accordance with ?240.13d-1(b)(1)(ii)(G); (h) ? A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ? A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) ? Group, in accordance with ?240.13d-1(b)(1)(ii)(J). Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 1, 202, 833 shares of common stock (b) Percent of class: 6.3% (c) N umber of shares as to which the person has: (i) Sole power to vote or to direct the vote . 00 1,202,833 (ii) Shared power to vote or to direct the vote . 00 (iii) Sole power to dispose or to direct the disposition of . 1,202,833 (iv) Shared power to dispose or to direct the disposition of . 00 Instruction. For computations regarding securities which represent a right to acquire an underlying security see ?240.13d-3(d)(1). Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ? . Instruction. Dissolution of a group requires a response to this item. Item 6. Ownership of More than Five Percent on Behalf of Another Person. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Item 8. Identification and Classification of Members of the Group. Item 9. Notice of Dissolution of Group. Item 10. Certification. ( a ) The following certification shall be included if the statement is filed pursuant to ?240.13d-1(c): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. 64132R 206 13G Page 3 of 3 Pages After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 3/21/2023 Date /s/ Signature Matthew Miller / Managing Partner Name/Title

Get the next $NRBO alert in real time by email

SEC Form SC 13G filed by NeuroBo Pharmaceuticals Inc.

Chat with this insight

Recent Analyst Ratings for
$NRBO

$NRBO
Press Releases

Fastest customizable press release news feed in the world

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

$NRBO
SEC Filings

NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by NeuroBo Pharmaceuticals Inc.

$NRBO
Large Ownership Changes

This live feed shows all institutional transactions in real time.